Explore news and
events about us

Aurigene in the media

Look at how we are addressing global patient needs with novel cancer therapeutics

July 5, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

BENGALURU, India--(BUSINESS WIRE)--The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development...

June 9, 2022

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited...

December 14, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial...

– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin...

News

July 5, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

BENGALURU, India--(BUSINESS WIRE)--The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development...

June 9, 2022

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited...

December 14, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial...

– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin...

February 19, 2020

Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis

PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis...

February 7, 2020

Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

PRESS RELEASE Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 - Aurigene to fund...

July 31, 2019

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement...

Events

Keep abreast of our presence at biotech and drug discovery events

May 10, 2022

May 10 – 12, 2022, Adenosine-Pathway Targeted Cancer Immunotherapy Summit

Dual Targeting of CD73 & A2AR for Effective Suppression of Adenosine Signaling May 11 2022

development of drugs and pharmaceutical industry

April 18, 2022

April 18-22, 2022, Drug Discovery Chemistry

Small Molecule Modulators of the Tumor Micro-Environment April 19, 2022

Warning: Undefined variable $post in /storage/v2188/aurigene-com/public_html/wp-content/themes/aurigene_child/components/event_listing.php on line 14

Warning: Attempt to read property "ID" on null in /storage/v2188/aurigene-com/public_html/wp-content/themes/aurigene_child/components/event_listing.php on line 14

November 5, 2022